Krystal Biotech, Inc. Common Stock
KRYSKrystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for dermatological and rare diseases. Established with the goal of advancing genetic medicine, it utilizes a proprietary viral vector platform to deliver gene therapies with the potential to treat conditions that have limited treatment options. The company's approach aims to provide targeted, durable treatments for patients suffering from various skin disorders and other genetic conditions.
Company News
The article highlights three biotech and semiconductor stocks that have more than doubled in the past 12 months but may have further upside potential. Abivax is advancing obefazimod for ulcerative colitis with strong clinical results. Krystal Biotech is generating strong revenue growth from its approved DEB treatment Vyjuvek with significant mark...
Three stocks—Moderna, Krystal Biotech, and AMD—have significantly outperformed the S&P 500 this year and are positioned for continued growth. Moderna is advancing toward approvals for its influenza and norovirus vaccines plus cancer vaccine candidates. Krystal Biotech's gene therapy Vyjuvek for rare skin disease is generating strong earnings ...
Krystal Biotech announced it will present on multiple gene therapy programs at scientific conferences in May and June 2026, including presentations on KB409/KB410 for primary ciliary dyskinesia at ASGCT, interim CORAL-1 trial results for KB407 in cystic fibrosis at ATS, and KB707 immunotherapy data at ASCO.
Vertex Pharmaceuticals faces potential competition from newer cystic fibrosis drugs like Krystal Biotech's KB407 gene therapy, which could work for all CF patients versus Vertex's limited mutation coverage. However, the company's core franchise appears safe through the late 2030s due to patent exclusivity, and Vertex is actively diversifying its ...
ACT Capital Management invested $7.25 million in Viking Therapeutics, acquiring 206,100 shares. Viking, a clinical-stage biotech company, is developing obesity and metabolic disorder treatments, with its lead candidate VK2735 showing promising Phase 2 results of up to 14.7% weight reduction. The company has $706 million in cash runway and is adva...
